Abstract
Administration of timolol to one eye is associated with a decrease in intraocular pressure in both eyes. To further investigate this effect the contralateral decrease in intraocular pressure was measured in a three arm crossover study using a 0.1 mg dose of timolol given topically to an eye, a 0.1 mg dose of timolol given lingually, and a placebo given topically. Two hours after topical timolol administration the mean intraocular pressure reduction in the fellow eye was 3.1 mm Hg compared with baseline (p = 0.0007). Two hours after lingual timolol administration the mean intraocular pressure reduction was 3.9 mm Hg compared with baseline (p = 0.0004). Two hours after topical administration of placebo the mean intraocular pressure reduction in the fellow eye was only 0.33 mm Hg (p = 0.6). These findings suggest the contralateral reduction in intraocular pressure from timolol is caused by systemic absorption. The significant intraocular pressure reduction obtained from lingual timolol raises the possibility that this route of drug administration may be useful in selected patients who cannot use eye drops.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alm A., Wickström C. P., Eckström C., Ohman L. The effect of metoprolol on intra-ocular pressure in glaucoma. A pilot study. Acta Ophthalmol (Copenh) 1979 Apr;57(2):236–242. doi: 10.1111/j.1755-3768.1979.tb00487.x. [DOI] [PubMed] [Google Scholar]
- Araie M., Takase M., Sakai Y., Ishii Y., Yokoyama Y., Kitagawa M. Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment. Jpn J Ophthalmol. 1982;26(3):248–263. [PubMed] [Google Scholar]
- Batchelor E. D., O'Day D. M., Shand D. G., Wood A. J. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979 Jan;86(1):60–65. doi: 10.1016/s0161-6420(79)35544-0. [DOI] [PubMed] [Google Scholar]
- Radius R. L., Diamond G. R., Pollack I. P., Langham M. E. Timolol. A new drug for management of chronic simple glaucoma. Arch Ophthalmol. 1978 Jun;96(6):1003–1008. doi: 10.1001/archopht.1978.03910050527005. [DOI] [PubMed] [Google Scholar]
- Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res. 1977;25 (Suppl):27–63. doi: 10.1016/s0014-4835(77)80009-2. [DOI] [PubMed] [Google Scholar]
- Shell J. W. Ophthalmic drug delivery systems. Surv Ophthalmol. 1984 Sep-Oct;29(2):117–128. doi: 10.1016/0039-6257(84)90168-1. [DOI] [PubMed] [Google Scholar]
- Steinert R. F., Thomas J. V., Boger W. P., 3rd Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981 Jan;99(1):100–103. doi: 10.1001/archopht.1981.03930010102012. [DOI] [PubMed] [Google Scholar]
- Urtti A., Salminen L. A comparison between iris-ciliary body concentration and receptor affinity of timolol. Acta Ophthalmol (Copenh) 1985 Feb;63(1):16–18. doi: 10.1111/j.1755-3768.1985.tb05207.x. [DOI] [PubMed] [Google Scholar]
- Zimmerman T. J., Kass M. A., Yablonski M. E., Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979 Apr;97(4):656–658. doi: 10.1001/archopht.1979.01020010312004. [DOI] [PubMed] [Google Scholar]
- Zimmerman T. J., Kaufman H. E. Timolol, dose response and duration of action. Arch Ophthalmol. 1977 Apr;95(4):605–607. doi: 10.1001/archopht.1977.04450040071009. [DOI] [PubMed] [Google Scholar]
- Zimmerman T. J., Kaufman H. E. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977 Apr;95(4):601–604. doi: 10.1001/archopht.1977.04450040067008. [DOI] [PubMed] [Google Scholar]
- Zimmerman T. J., Kooner K. S., Kandarakis A. S., Ziegler L. P. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984 Apr;102(4):551–553. doi: 10.1001/archopht.1984.01040030429017. [DOI] [PubMed] [Google Scholar]